Gastroesophageal in Medical Technology

Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium

... Standard Infusional Chemotherapy in gastroesophageal and Colorectal Cancers - NUTLEY, N.J., Jan. 24 ... of intravenous fluorouracil (5-FU) therapy in gastroesophageal cancer. A second pair of U.S. abstracts evaluates ... capecitabine treatment patterns in patients with gastroesophageal cancer (GEC) (Presenter: Wasif Saif) -- Jan. ...

Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development

... their patients with this disease." As a result of chronic injury from gastroesophageal reflux disease (GERD), the normal esophageal lining is replaced with ... condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a ...

Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination

... with the HALO ablation system. Barrett's esophagus is a complication of gastroesophageal reflux disease (GERD) and is a known risk factor for esophageal cancer, ... condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its flagship product, the HALO360 System, ...

FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)

... Pump Inhibitors (PPIs) have been shown to be beneficial for patients with gastroesophageal reflux disease (GERD). PPIs are generally well tolerated and ... for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease. PRILOSEC is also indicated for the short-term treatment (4 ...

Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms

... N, Monyak J, Silberg, D: Effect of Obesity Resolution in Patients with gastroesophageal Reflux Disease (GERD). The American College of Gastroenterology Annual ... H, Abraham NS, and El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199-211. ...

It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer

... at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major ... men but can affect anyone, even those who do not have obvious symptoms of gastroesophageal reflux disease. To learn more about Barrett's esophagus or to schedule an ...

Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease

... and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) ... agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan Biosciences, ...

Definitive Outcomes of Radiofrequency Ablation for Barrett's Esophagus Using the HALO Ablation System Reported at the Digestive Disease Week Meeting for Gastroenterologists and Esophageal Surgeons

... Inc. develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue ...

Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's Esophagus

... Inc. develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue ...

American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought

... authority. ABSTRACT: Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma: A Randomized Controlled Trial Background: gastroesophageal reflux (GER) is common in asthma patients but often has mild or no symptoms. It is not known whether treatment of GER with proton pump inhibitors ...

Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment

... ST. PAUL, Minn., April 3 /PRNewswire/ -- Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) Reflux Management System. The trial, which is being conducted at 15 ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome and is generally its most prominent component. In patients who take opiates chronically for ...

Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System

... studies estimate that Barrett's esophagus affects approximately six million European and US adults and is a complication of a disorder called gastroesophageal reflux disease or GERD. Once diagnosed, Barrett's can worsen over time, developing dysplasia and esophageal adenocarcinoma (cancer), as in this ....

Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed

... for Patients with Healed Erosive Esophagitis (EE). Abstract P21, Poster Presentation, Sunday, October 5 -- TAK-390MR Maintains Relief of gastroesophageal Reflux Disease (GERD) Symptoms and Improvements in Quality of Life in GERD Patients with Healed Erosive Esophagitis. Abstract P24, Poster ...

TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis

... "These maintenance results coupled with the overall healing results are encouraging for the potential of TAK-390MR in treating patients with gastroesophageal reflux disease." About TAK-390MR TAK-390MR, an enantiomer of lansoprazole, employs an innovative dual delayed release technology, which is ...

FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents

... and Drug Administration (FDA) has accepted an ACIPHEX supplemental New Drug Application (sNDA) for the short-term (up to eight weeks) treatment of gastroesophageal reflux disease (GERD) in patients ages 12-16. Further, FDA has indicated that the sNDA will receive priority review in accordance with the Best ...

EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study

... City, California. EGS is a pioneer in developing incisionless transoral procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI conditions. EsophyX and StomaphyX(TM) are cleared by the FDA for specific indications, are CE marked, and are ...

Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction

... nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. Currently, there are no specific drugs approved ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... with solid tumors. Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD). This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. Head and Neck Cancer Taxotere(R) in combination with cisplatin and ...

Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease

... other gastrointestinal and liver diseases including Pouchitis, Hepatic Encephalopathy, Irritable Bowel Syndrome and Proton Pump Inhibitor-resistant gastroesophageal Reflux Disease. Ocera Therapeutics has raised $26.5 million dollars in venture financing from Domain Associates, Sofinnova Ventures and Thomas, ...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

... a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com . This press ...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

... a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan Biosciences, please visit the Company's website at http://www.kosan.com . This press ...

New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting

... studies today regarding pediatric patients with gastroesophageal reflux disease (GERD) during oral and ... Esophagitis (EE) and Improvement in Symptoms of gastroesophageal Reflux Disease (GERD) in 1- and ... Convention Center Effect of Esomeprazole on gastroesophageal Reflux Measured by 24-hour pH- Impedance ...

Dynogen Reports Positive Results in Phase 1B GERD Study

... DDP733 as a treatment for GERD. About Nocturnal gastroesophageal Reflux Disease (NGERD) gastroesophageal reflux disease (GERD) is a chronic condition that ... of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The ...

Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

... a treatment for GERD. About Nocturnal gastroesophageal Reflux Disease (NGERD) gastroesophageal reflux disease (GERD) is a chronic condition that ... of life, such as irritable bowel syndrome, gastroesophageal reflux disease and overactive bladder. The ...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

... for the treatment of cancer: -- "Activity of PXD101, an HDAC inhibitor, used alone or in combination with 5-FU in preclinical gastroesophageal studies," (Abstract #691) during the conference's HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall, ...

XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome

... neuralgia. XenoPort has also reported positive results from a Phase 2a clinical trial of its second product candidate, XP19986, in patients with gastroesophageal reflux disease. To learn more about XenoPort, please visit the web site at www.XenoPort.com. Forward-Looking Statements This press release ...

DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia

... and ultimately, esophageal cancer. Barrett's esophagus affects an estimated 700,000 adults in the United States and is often associated with gastroesophageal reflux disease or GERD. Treatments currently available for severe precancerous tissue changes or high grade dysplasia, include highly ...